Veracyte (NASDAQ:VCYT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

20 Dec 2025, 17:02 by Doug Wharley · The Cerbat Gem

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Veracyte, Inc. (NASDAQ:VCYT). In a filing disclosed on December 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Veracyte stock on November 12th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Veracyte Stock Up 2.1%

Shares of NASDAQ VCYT traded up $0.88 during trading hours on Friday, hitting $42.92. 1,159,960 shares of the stock were exchanged, compared to its average volume of 903,586. The firm has a fifty day moving average price of $40.91 and a 200-day moving average price of $33.07. The company has a market cap of $3.39 billion, a PE ratio of 112.95 and a beta of 1.83. Veracyte, Inc. has a 12 month low of $22.61 and a 12 month high of $50.71.

Veracyte (NASDAQ:VCYT – Get Free Report) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.19. The firm had revenue of $131.87 million for the quarter, compared to the consensus estimate of $124.62 million. Veracyte had a return on equity of 7.23% and a net margin of 6.12%.The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 EPS. As a group, equities analysts anticipate that Veracyte, Inc. will post 0.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on VCYT. Needham & Company LLC raised their target price on Veracyte from $41.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Veracyte in a research report on Monday. Guggenheim boosted their price objective on Veracyte from $40.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Zacks Research raised Veracyte from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Finally, Morgan Stanley raised their price target on shares of Veracyte from $40.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Veracyte currently has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Get Our Latest Report on VCYT

Hedge Funds Weigh In On Veracyte

A number of large investors have recently modified their holdings of VCYT. First Horizon Corp purchased a new position in shares of Veracyte during the 3rd quarter worth $31,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Veracyte in the second quarter valued at approximately $25,000. Osaic Holdings Inc. grew its holdings in Veracyte by 289.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,201 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 893 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Veracyte during the 3rd quarter valued at approximately $56,000. Finally, Headlands Technologies LLC raised its holdings in Veracyte by 74.8% in the second quarter. Headlands Technologies LLC now owns 2,824 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,208 shares in the last quarter.

Insider Buying and Selling

In other Veracyte news, CFO Rebecca Chambers sold 13,278 shares of Veracyte stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $46.84, for a total value of $621,941.52. Following the transaction, the chief financial officer owned 109,496 shares in the company, valued at approximately $5,128,792.64. The trade was a 10.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc Stapley sold 7,668 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $47.09, for a total transaction of $361,086.12. Following the completion of the sale, the chief executive officer owned 318,603 shares of the company’s stock, valued at approximately $15,003,015.27. This trade represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 142,984 shares of company stock worth $6,282,692. 1.40% of the stock is currently owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.